• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Gubra

374.80 DKK-1.06 %30/7 13:17
Less than 1K followers

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.06 %
+15.68 %
+18.01 %
-14.15 %
-27.57 %
-1.52 %
+316.40 %
-
+240.73 %

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more
Market cap
6.16B DKK
Turnover
1.29M DKK
Revenue
2.64B
EBIT %
81.54 %
P/E
3.61
Dividend yield-%
-
Coverage
Disclaimer
Michael Friis
Michael Friis

Head of Equities

Latest research

Latest analysis report

Released: 2026-05-13

Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

3/3
2027

Annual report '26

Gubra: UCN2 enters the clinic with an ambitious Phase 1/2a design and an R&D Day date
Analyst Comment2026-07-28 08:50 by
Michael Friis

Gubra: UCN2 enters the clinic with an ambitious Phase 1/2a design and an R&D Day date

Gubra this morning announced the initiation of the first-in-human trial of GUB-UCN2, the company's wholly owned muscle-sparing obesity candidate, with the first participant having completed the first visit. The event confirms the FPFV timeline of H2 2026.

Gubra
Press release2026-07-28 07:00

Gubra announces initiation of ambitious Phase 1/2a clinical trial of lead asset GUB-UCN2 in obesity

Gubra
Gubra: Boehringer Ingelheim initiates Phase 2 of triple agonist, triggering EUR 10m milestone
Analyst Comment2026-07-16 07:49 by
Michael Friis

Gubra: Boehringer Ingelheim initiates Phase 2 of triple agonist, triggering EUR 10m milestone

Gubra today announced that its partner Boehringer Ingelheim has initiated Phase 2 clinical development of BI 3034701, a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide, triggering EUR 10m in milestones.

Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-16 07:00

Boehringer Ingelheim initiates Phase 2 clinical trial of Gubra-originated triple receptor agonist for people living with overweight and obesity

Gubra
Press release2026-07-10 08:00

Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress

Gubra
Regulatory press release2026-07-08 20:00

Major shareholder announcement: The Capital Group Companies, Inc.

Gubra
Regulatory press release2026-07-06 09:00

Share repurchase for employee incentive programs

Gubra
Regulatory press release2026-06-30 17:30

Major shareholder announcement: The Capital Group Companies, Inc.

Gubra
Regulatory press release2026-06-30 17:15

Share capital and total number of voting rights as of 30 June 2026

Gubra
Regulatory press release2026-06-17 23:29

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Regulatory press release2026-06-17 23:12

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Press release2026-06-16 07:30

Gubra Appoints Lena Moran-Adams as Group General Counsel

Gubra
Regulatory press release2026-06-10 22:25

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Regulatory press release2026-06-10 22:14

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Regulatory press release2026-06-08 15:09

Gubra capital increase in connection with exercise of warrants

Gubra
Regulatory press release2026-06-04 10:29

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Regulatory press release2026-06-04 10:19

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Press release2026-05-19 07:30

Gubra Appoints Adam Lange as Head of Investor Relations

Gubra
Gubra (One-pager): A clinically pivotal quarter, with two obesity assets advancing toward Phase 2
Research2026-05-13 10:45 by
Michael Friis, Victor Skriver

Gubra (One-pager): A clinically pivotal quarter, with two obesity assets advancing toward Phase 2

We have updated our One-pager investment case on Gubra to reflect the Q1 2026 trading statement, the revised CRO guidance, and the clinical newsflow across the pipeline. The quarter has incrementally strengthened the D&P-driven equity value case, while the CRO downgrade has only a limited impact on our valuation framework given the segment's modest share of total enterprise value.

Gubra
Regulatory press release2026-05-12 16:41

Gubra initiates employee share matching program

Gubra